Research & Development
REGiMMUNE launches Phase I/II trial of RGI-2001
1 February 2012 - REGiMMUNE Corporation announced on Tuesday the launch of its Phase I/II study of the RGI-2001 compound for Graft versus Host Disease (GvHD) associated with hematopoietic stem cell transplantation.

The study will enrol some 50 bone marrow or peripheral blood stem cell trans...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up

 

 

 

Login
Username:

Password: